Gene therapy is poised to break the stratosphere, providing many rare disease patients with an option out of their diseases. Whether innovations in CAR T-cell therapy or the rise of CRISPR, never before have patients had such a variety of therapeutic options becoming available.
And the future is here. Just last December, the U.S. Food and Drug Administration (FDA) approved the first two cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older—one of which utilizes CRISPR technology.
However, one glaring issue is blocking the path to success: who pays for the treatment?
More information read here - https://bio.news/health/bio-2024-international-convention-gene-therapy-payment-models-bluebird-bio-vertex-pharmaceuticals/?fbclid=IwZXh0bgNhZW0CMTEAAR0Vn2LNtTHn4qcGwA7ffasyJQZyGJqzVut98f9J3OtWHTb9eCLK5PLr-Ik_aem_71qOwLShNmEfie4uslcTPA
Share This News